Literature DB >> 20420365

Fullerene-conjugated doxorubicin in cells.

Jia-Hui Liu1, Li Cao, Pengju G Luo, Sheng-Tao Yang, Fushen Lu, Haifang Wang, Mohammed J Meziani, Sk Anwarul Haque, Yuanfang Liu, Sebastian Lacher, Ya-Ping Sun.   

Abstract

The conjugation of fullerene with well-established drug molecules has been a representative strategy to impart fullerene-specific properties for improved formulation. However, conjugates involving fullerenes or other nanomaterials often differ significantly from the free drug molecules in cellular uptake and distributions. For the highly effective anticancer drug doxorubicin (DOX), its strong absorption and fluorescence in the visible spectral region enable the tracking of DOX-containing conjugates by optical techniques. In this work, a stoimetrically and structurally well-defined fullerene-DOX conjugate was studied in terms of fluorescence microscopy, including the fluorescence imaging with two-photon excitation, to examine the uptake and distribution in human breast cancer cells. The results suggested that the conjugate was distributed mostly in the cytoplasm, significantly different from free DOX molecules (predominantly in the cell nucleus, as already reported in the literature). Mechanistic implications of the results are discussed. Also discussed are potentials of conjugated DOX species as self-labeled fluorescent probes in bioimaging and other mechanistic investigations on drug delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20420365     DOI: 10.1021/am100037y

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  14 in total

1.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

2.  The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma.

Authors:  Norman A Lapin; Martyna Krzykawska-Serda; Sean Dilliard; Yuri Mackeyev; Maciej Serda; Lon J Wilson; Steven A Curley; Stuart J Corr
Journal:  J Control Release       Date:  2017-05-17       Impact factor: 9.776

3.  Synthesis and evaluation of anticancer activity in cells of novel stoichiometric pegylated fullerene-doxorubicin conjugates.

Authors:  George E Magoulas; Marina Bantzi; Danai Messari; Efstathia Voulgari; Chrisostomi Gialeli; Despoina Barbouri; Athanassios Giannis; Nikos K Karamanos; Dionissios Papaioannou; Konstantinos Avgoustakis
Journal:  Pharm Res       Date:  2014-11-08       Impact factor: 4.200

4.  C60 fullerene affects elastic properties and osmoregulation reactions of human lymphocytes.

Authors:  Marina Yu Skorkina; Evgenia A Sladkova; Elena A Shamray; Olga V Cherkashina; Maxim P Evstigneev; Anatoly S Buchelnikov; Yuriy I Prylutskyy; Uwe Ritter
Journal:  Eur Biophys J       Date:  2015-06-14       Impact factor: 1.733

5.  Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Biother Radiopharm       Date:  2011-12-22       Impact factor: 3.099

6.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

7.  Novel meso-substituted porphyrin derivatives and its potential use in photodynamic therapy of cancer.

Authors:  Pablo Vallecorsa; Gabriela Di Venosa; M Belén Ballatore; Dario Ferreyra; Leandro Mamone; Daniel Sáenz; Gustavo Calvo; Edgardo Durantini; Adriana Casas
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.430

8.  Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2015-01

9.  Study of the cytotoxic effects of the new synthetic Isothiocyanate CM9 and its fullerene derivative on human T-leukemia cells.

Authors:  Elena De Gianni; Eleonora Turrini; Andrea Milelli; Francesca Maffei; Marco Carini; Anna Minarini; Vincenzo Tumiatti; Tatiana Da Ros; Maurizio Prato; Carmela Fimognari
Journal:  Toxins (Basel)       Date:  2015-02-11       Impact factor: 4.546

10.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Res Ther Oncol       Date:  2014-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.